Cargando…

Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis

OBJECTIVE: Post-translational protein modifications with malondialdehyde-acetaldehyde (MAA) and citrulline (CIT) are implicated in the pathogenesis of rheumatoid arthritis (RA). Although precise mechanisms have not been elucidated, macrophage-fibroblast interactions have been proposed to play a cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Aripova, Nozima, Duryee, Michael J., England, Bryant R., Hunter, Carlos D., Mordeson, Jack E., Ryan, Evan M., Daubach, Eric C., Romberger, Debra J., Thiele, Geoffrey M., Mikuls, Ted R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467288/
https://www.ncbi.nlm.nih.gov/pubmed/37654483
http://dx.doi.org/10.3389/fimmu.2023.1203548
_version_ 1785099083807981568
author Aripova, Nozima
Duryee, Michael J.
England, Bryant R.
Hunter, Carlos D.
Mordeson, Jack E.
Ryan, Evan M.
Daubach, Eric C.
Romberger, Debra J.
Thiele, Geoffrey M.
Mikuls, Ted R.
author_facet Aripova, Nozima
Duryee, Michael J.
England, Bryant R.
Hunter, Carlos D.
Mordeson, Jack E.
Ryan, Evan M.
Daubach, Eric C.
Romberger, Debra J.
Thiele, Geoffrey M.
Mikuls, Ted R.
author_sort Aripova, Nozima
collection PubMed
description OBJECTIVE: Post-translational protein modifications with malondialdehyde-acetaldehyde (MAA) and citrulline (CIT) are implicated in the pathogenesis of rheumatoid arthritis (RA). Although precise mechanisms have not been elucidated, macrophage-fibroblast interactions have been proposed to play a central role in the development and progression of RA. The purpose of our study was to evaluate the downstream effects of macrophage released soluble mediators, following stimulation with fibrinogen (FIB) modified antigens, on human fibroblast-like synoviocytes (HFLS). METHODS: PMA-treated U-937 monocytes (Mϕ) and macrophage-differentiated peripheral blood mononuclear cells (MP) were stimulated with FIB, FIB-MAA, FIB-CIT, or FIB-MAA-CIT. HFLS-RA cells were stimulated directly with FIB antigens or with supernatants (SN) from macrophages (Mϕ-SN or MP-SN) stimulated with FIB antigens. Genes associated with an aggressive HFLS phenotype, extracellular matrix proteins, and activated signaling pathways were evaluated. RESULTS: HFLS-RA cells treated with Mϕ-SN(FIB-CIT) and Mϕ-SN(FIB-MAA-CIT) demonstrated significant increases in mRNA expression of genes associated with an aggressive phenotype at 24-h as compared to direct stimulation with the same antigens. Similar results were obtained using MP-SN. Cellular morphology was altered and protein expression of vimentin (p<0.0001 vs. Mϕ-SN(FIB)) and type II collagen (p<0.0001) were significantly increased in HFLS-RA cells treated with any of the Mϕ-SN generated following stimulation with modified antigens. Phosphorylation of JNK, Erk1/2, and Akt were increased most substantially in HFLS-RA treated with Mϕ-SN(FIB-MAA-CIT) (p<0.05 vs Mϕ-SN(FIB)). These and other data suggested the presence of PDGF-BB in Mϕ-SN. Mϕ-SN(FIB-MAA-CIT) contained the highest concentration of PDGF-BB (p<0.0001 vs. Mϕ-SN(FIB)) followed by Mϕ-SN(FIB-CIT) then Mϕ-SN(FIB-MAA). HFLS-RA cells treated with PDGF-BB showed similar cellular morphology to the Mϕ-SN generated following stimulation with modified FIB, as well as the increased expression of vimentin, type II collagen, and the phosphorylation of JNK, Erk1/2 and Akt signaling molecules. CONCLUSION: Together, these findings support the hypothesis that in response to MAA-modified and/or citrullinated fibrinogen, macrophages release soluble factors including PDGF-BB that induce fibroblast activation and promote an aggressive fibroblast phenotype. These cellular responses were most robust following macrophage activation with dually modified fibrinogen, compared to single modification alone, providing novel insights into the combined role of multiple post-translational protein modifications in the development of RA.
format Online
Article
Text
id pubmed-10467288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104672882023-08-31 Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis Aripova, Nozima Duryee, Michael J. England, Bryant R. Hunter, Carlos D. Mordeson, Jack E. Ryan, Evan M. Daubach, Eric C. Romberger, Debra J. Thiele, Geoffrey M. Mikuls, Ted R. Front Immunol Immunology OBJECTIVE: Post-translational protein modifications with malondialdehyde-acetaldehyde (MAA) and citrulline (CIT) are implicated in the pathogenesis of rheumatoid arthritis (RA). Although precise mechanisms have not been elucidated, macrophage-fibroblast interactions have been proposed to play a central role in the development and progression of RA. The purpose of our study was to evaluate the downstream effects of macrophage released soluble mediators, following stimulation with fibrinogen (FIB) modified antigens, on human fibroblast-like synoviocytes (HFLS). METHODS: PMA-treated U-937 monocytes (Mϕ) and macrophage-differentiated peripheral blood mononuclear cells (MP) were stimulated with FIB, FIB-MAA, FIB-CIT, or FIB-MAA-CIT. HFLS-RA cells were stimulated directly with FIB antigens or with supernatants (SN) from macrophages (Mϕ-SN or MP-SN) stimulated with FIB antigens. Genes associated with an aggressive HFLS phenotype, extracellular matrix proteins, and activated signaling pathways were evaluated. RESULTS: HFLS-RA cells treated with Mϕ-SN(FIB-CIT) and Mϕ-SN(FIB-MAA-CIT) demonstrated significant increases in mRNA expression of genes associated with an aggressive phenotype at 24-h as compared to direct stimulation with the same antigens. Similar results were obtained using MP-SN. Cellular morphology was altered and protein expression of vimentin (p<0.0001 vs. Mϕ-SN(FIB)) and type II collagen (p<0.0001) were significantly increased in HFLS-RA cells treated with any of the Mϕ-SN generated following stimulation with modified antigens. Phosphorylation of JNK, Erk1/2, and Akt were increased most substantially in HFLS-RA treated with Mϕ-SN(FIB-MAA-CIT) (p<0.05 vs Mϕ-SN(FIB)). These and other data suggested the presence of PDGF-BB in Mϕ-SN. Mϕ-SN(FIB-MAA-CIT) contained the highest concentration of PDGF-BB (p<0.0001 vs. Mϕ-SN(FIB)) followed by Mϕ-SN(FIB-CIT) then Mϕ-SN(FIB-MAA). HFLS-RA cells treated with PDGF-BB showed similar cellular morphology to the Mϕ-SN generated following stimulation with modified FIB, as well as the increased expression of vimentin, type II collagen, and the phosphorylation of JNK, Erk1/2 and Akt signaling molecules. CONCLUSION: Together, these findings support the hypothesis that in response to MAA-modified and/or citrullinated fibrinogen, macrophages release soluble factors including PDGF-BB that induce fibroblast activation and promote an aggressive fibroblast phenotype. These cellular responses were most robust following macrophage activation with dually modified fibrinogen, compared to single modification alone, providing novel insights into the combined role of multiple post-translational protein modifications in the development of RA. Frontiers Media S.A. 2023-08-16 /pmc/articles/PMC10467288/ /pubmed/37654483 http://dx.doi.org/10.3389/fimmu.2023.1203548 Text en Copyright © 2023 Aripova, Duryee, England, Hunter, Mordeson, Ryan, Daubach, Romberger, Thiele and Mikuls https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Aripova, Nozima
Duryee, Michael J.
England, Bryant R.
Hunter, Carlos D.
Mordeson, Jack E.
Ryan, Evan M.
Daubach, Eric C.
Romberger, Debra J.
Thiele, Geoffrey M.
Mikuls, Ted R.
Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title_full Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title_fullStr Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title_full_unstemmed Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title_short Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
title_sort citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467288/
https://www.ncbi.nlm.nih.gov/pubmed/37654483
http://dx.doi.org/10.3389/fimmu.2023.1203548
work_keys_str_mv AT aripovanozima citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT duryeemichaelj citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT englandbryantr citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT huntercarlosd citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT mordesonjacke citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT ryanevanm citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT daubachericc citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT rombergerdebraj citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT thielegeoffreym citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis
AT mikulstedr citrullinatedandmalondialdehydeacetaldehydemodifiedfibrinogenactivatesmacrophagesandpromotesanaggressivesynovialfibroblastphenotypeinpatientswithrheumatoidarthritis